Want to join the conversation?
$AGN's Namenda XR revenues for 1Q16 were $173MM, as prescriptions and formulary coverage remained stable following the loss of exclusivity of Namenda IR. Lumigan/Ganfort revenues were $170MM reflecting stable performance across its glaucoma product franchise. Bystolic revenues remained stable at $164MM.
$WBA is yet to receive US anti-trust clearance for its Rite Aid acquisition. The deadline for the deal expires on January 27.
$BMY plunge 7.2%. No credits to the non-acceleration of approval for lung cancer combination treatment.
Well this is big! I don’t know if it’s someone’s monopoly or genuine excitement, but either way, $CSX is up 23% after market closed. I heard some activist investor is going to blow big money into CSX Corp. Anyone mind explaining?